COVID-19: optimization of respiratory biomechanics by aerosol pus solvent

Feature of the course of the disease caused by coronavirus is the development of severe non-specific pneumonia, which disrupts gas exchange in the respiratory system and causes hypoxia. To save the life of patients in the critical stage of non-specific pneumonia, it is necessary to eliminate hypoxia. For this purpose, forced mechanical ventilation of the lungs using breathing gases enriched with oxygen is widely used. However, increasing the pressure, volume, and concentration of oxygen gas in the inhaled air does not always eliminate hypoxia in patients with COVID -19. The fact is that in this disease, the cause of the suffocation symptom is thick mucus and pus that fill the lumen of the bronchi. It is the mucus and pus that clog the bronchi that do not allow restoring airiness of the lungs, gas exchange and blood oxygenation in non-specific pneumonia. In this regard, it is the obstruction of the bronchi caused by mucus and pus that causes the critical stage of the disease in non-specific pneumonia caused by coronavirus. In these conditions, due to the lack of mucolytic aerosol for inhalation that would effectively dissolve thick mucus and thick pus, there is nothing left to save the patient's life but to eliminate hypoxia using extracorporeal membrane oxygenation. However, extracorporeal membrane oxygenation is a very expensive and very dangerous method of treatment, which itself causes the death of almost half of patients. In this regard, to increase the effectiveness of forced lung ventilation, it is proposed to use a special aerosol that, when inhaled, can quickly dissolve mucus and pus in the bronchi and remove them outside. The formulation of such an aerosol is given and an example of its effectiveness in obstructive bronchitis is described.